CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) stock intrinsic value fair value estimate & owner earnings analysis

Clover Health is a Medicare Advantage (MA) insurer offering PPO and HMO plans built around a proprietary tool called Clover Assistant, which gives treating physicians point-of-care guidance intended to catch and manage chronic conditions earlier and help hold down medical costs. Membership is heavily concentrated: in the most recently completed fiscal year, about 87% of members lived in New Jersey, mostly in two metropolitan areas, with a smaller presence in Texas and a handful of other states (New York, Michigan, New Hampshire, North Carolina, Vermont) where the company is licensed but has not yet built meaningful membership. Between 2022 and 2024 the company narrowed its focus considerably, exiting a large government direct-contracting program and winding down an in-home care service. The last two full years (2024 and 2025) are the cleanest picture of the business as it exists today: an insurance-only operation growing its core Medicare Advantage membership quickly (roughly 33% growth in average members in 2025) while shrinking overhead as a share of premium. That growth has come at a cost. Medical claims rose 56% in 2025, driven by the membership growth itself, a higher share of catastrophic-phase drug cost the company now bears following the 2025 Medicare Part D benefit redesign under the Inflation Reduction Act, and the fact that 2024's results had been flattered by an unusually favorable, one-time reserve adjustment that did not repeat in 2025. Together these pushed the company to a net loss of about $86 million in 2025, after a much smaller loss of $43 million in 2024. In building an estimate of the cash the business actually generates for owners, we treated stock-based compensation (a real, if non-cash, cost) as a full deduction, and we backed out the swings in claims reserves and receivables that come with fast membership growth, since these are timing effects rather than a permanent drag. The first half of 2026 tells a different story: two consecutive profitable quarters, versus a loss in the same period of 2025, with medical costs as a share of premium holding roughly steady even as membership kept growing. That is a real, already-reported data point, not a projection, and it is the main reason the cases below assume the business becomes durably profitable rather than continuing to lose money. It is worth being direct about the limits of that evidence: two quarters is a short track record for a company whose results have swung by tens of millions of dollars in the past because of how claims reserves develop over time, and the most recent full filing available to us does not let us fully rule out that some of the early-2026 improvement reflects reserve timing rather than a genuinely lower underlying cost trend. CMS, the federal agency that rates and pays Medicare Advantage plans, recently raised the quality ("Star") rating on Clover's HMO plan and held its PPO rating steady for the 2026 rating year, which will translate into higher bonus payments starting in 2027. The company has also disclosed that its membership includes a higher share of lower-income and minority beneficiaries than many competitors, which by its own account makes it structurally harder to sustain top-tier Star ratings going forward - an ongoing risk to bonus revenue, not a one-time item. Bear case (roughly $0.50/share): the 2026 turn to profitability doesn't hold. Medical costs stay elevated, a Star rating slips, and competition from larger, better-capitalized insurers active in the same New Jersey market limits growth to the low single digits. The business essentially treads water for a decade without building real value. Base case (roughly $13/share): profitability holds and gradually strengthens as membership growth - moderating over time as the core New Jersey market matures - and the 2027 Star bonus flow through, while medical costs stabilize modestly below the 2025 level rather than swinging back to 2024's unusually favorable low point. Bull case (roughly $26/share): the company's own cost-management technology keeps working the way it has shown it can - physicians who use Clover Assistant have produced lower medical costs than those who don't, per the company's own data - so the medical cost ratio approaches 2024's low again, membership growth continues at a strong pace for longer, and the New Jersey concentration risk fades as the newer, currently small states scale up. Clover has no outstanding debt (the last borrowings were repaid by the end of 2022), so none of the figures above needed to be reduced for lenders' claims; as a regulated insurer, we valued its stream of earnings after interest directly rather than separately subtracting debt. Given how recent and short the evidence for a profitable turn is, the margin-of-safety price is set at a large discount to our base-case estimate - roughly $5.50 a share - and assumes one or two more profitable quarters confirm that the early-2026 improvement was not a temporary reserve-timing benefit.